Long-lasting pain and somatosensory disturbances in children with myelin oligodendrocyte glycoprotein antibody-associated disease.
Acquired demyelinating syndrome
Children
Myelin oligodendrocyte glycoprotein antibody-associated disease
Pain
Somatosensory disturbance
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
05
01
2023
accepted:
17
04
2023
revised:
22
03
2023
medline:
21
7
2023
pubmed:
29
4
2023
entrez:
29
4
2023
Statut:
ppublish
Résumé
Myelin oligodendrocyte glycoprotein antibody (MOG-Ab) is an autoantibody associated with acquired demyelinating syndrome (ADS) in childhood and adults. The pathogenic roles of MOG-Ab and long-term outcomes of children with MOG-Ab-associated disease (MOGAD) remain elusive. We investigated the clinical features of children with ADS during follow-up in our institute. Clinical data were retrospectively analyzed using medical charts of patients managed in Kyushu University Hospital from January 1st, 2001, to March 31st, 2022. Participants were children of < 18 years of age when they received a diagnosis of ADS in our hospital. Cell-based assays were used to detect MOG-Ab in serum or cerebrospinal fluid at the onset or recurrence of ADS. The clinical and neuroimaging data of MOG-Ab-positive and MOG-Ab-negative patients were statistically analyzed. Among 31 patients enrolled in this study, 22 (13 females, 59%) received tests for MOG antibodies. Thirteen cases (59%) were MOG-Ab-positive and were therefore defined as MOGAD; 9 (41%) were MOG-Ab-negative. There were no differences between MOGAD and MOG-Ab-negative patients in age at onset, sex, diagnostic subcategories, or duration of follow-up. MOGAD patients experienced headache and/or somatosensory symptoms more frequently than MOG-Ab-negative patients (12/13 (92%) vs. 3/9 (22%); p = 0.0066). Somatosensory problems included persistent pain with hyperesthesia in the left toe, perineal dysesthesia, and facial hypesthesia. No specific neuroimaging findings were associated with MOGAD or the presence of somatosensory symptoms. Long-lasting somatosensory disturbances are prominent comorbidities in children with MOGAD. Prospective cohorts are required to identify molecular and immunogenetic profiles associated with somatosensory problems in MOGAD. • Recurrence of demyelinating events occurs in a group of children with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). • Long-lasting headache and somatosensory problems are frequent comorbidities with pediatric MOGAD. Pain and somatosensory problems may persist for more than 5 years. • Neuroimaging data do not indicate specific findings in children with somatic disturbances.
Identifiants
pubmed: 37119299
doi: 10.1007/s00431-023-04989-z
pii: 10.1007/s00431-023-04989-z
doi:
Substances chimiques
Myelin-Oligodendrocyte Glycoprotein
0
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3175-3185Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP17K16271
Organisme : Japan Society for the Promotion of Science
ID : JP19K10613
Organisme : Japan Society for the Promotion of Science
ID : JP22K07893
Organisme : Japan Society for the Promotion of Science
ID : JP21K07464
Organisme : Ministry of Health, Labour and Welfare
ID : JP22HA1003
Organisme : Ministry of Health, Labour and Welfare
ID : JP20FC1030
Organisme : Japan Agency for Medical Research and Development
ID : JP21zf0127004
Organisme : Japan Agency for Medical Research and Development
ID : JP20ek0109411
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Marignier R, Hacohen Y, Cobo-Calvo A, Probstel AK, Aktas O, Alexopoulos H, Amato MP et al (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20:762–772
pubmed: 34418402
Armangue T, Olive-Cirera G, Martinez-Hernandez E, Sepulveda M, Ruiz-Garcia R, Munoz-Batista M, Arino H, Gonzalez-Alvarez V, Felipe-Rucian A, Jesus Martinez-Gonzalez M, Cantarin-Extremera V, Concepcion Miranda-Herrero M, Monge-Galindo L, Tomas-Vila M, Miravet E, Malaga I, Arrambide G, Auger C, Tintore M, Montalban X, Vanderver A, Graus F, Saiz A, Dalmau J, Pediatric S, anti MOGSG, (2020) Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol 19:234–246
pubmed: 32057303
Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM (2011) Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 14:1142–1149
pubmed: 21804537
Asseyer S, Cooper G, Paul F (2020) Pain in NMOSD and MOGAD: a systematic literature review of pathophysiology, symptoms, and current treatment strategies. Front Neurol 11:778
pubmed: 33473247
pmcid: 7812141
Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15:89–102
pubmed: 30559466
Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kumpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15:134
pubmed: 29724224
pmcid: 5932838
Bruijstens AL, Breu M, Wendel EM, Wassmer E, Lim M, Neuteboom RF, Wickstrom R, consortium EUpM, Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostasy K, (2020) E.U. paediatric MOG consortium consensus: part 4 - outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29:32–40
pubmed: 33183945
Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostasy K, consortium EUpM, (2020) E.U. paediatric MOG consortium consensus: part 2 - neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29:14–21
pubmed: 33158737
Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, Karenfort M, Selch C, Hausler M, Eisenkolbl A, Salandin M, Gruber-Sedlmayr U, Blaschek A, Kraus V, Leiz S, Finsterwalder J, Gotwald T, Kuchukhidze G, Berger T, Reindl M, Rostasy K (2015) Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 86:265–272
pubmed: 25121570
Satukijchai C, Mariano R, Messina S, Sa M, Woodhall MR, Robertson NP, Ming L, Wassmer E, Kneen R, Huda S, Jacob A, Blain C, Halfpenny C, Hemingway C, O’Sullivan E, Hobart J, Fisniku LK, Martin R, Dopson R, Cooper SA, Williams V, Waters PJ, Ramdas S, Leite MI, Palace J (2022) Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom. JAMA Netw Open 5:e2142780
pubmed: 35006246
pmcid: 8749481
Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakazawa T, Nakashima I (2021) Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease. Mult Scler Relat Disord 56:103222
pubmed: 34461572
Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, Sato DK, Nishiyama S, Misu T, Kuroda H, Aoki M, Fujihara K (2017) MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4:e322
pubmed: 28105459
pmcid: 5241006
Bartels F, Lu A, Oertel FC, Finke C, Paul F, Chien C (2021) Clinical and neuroimaging findings in MOGAD-MRI and OCT. Clin Exp Immunol 206:266–281
pubmed: 34152000
pmcid: 8561692
Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, Chitnis T (2016) Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 22:174–184
pubmed: 26041801
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW, Scher AI, Munger KL, Ascherio A (2022) Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375:296–301
pubmed: 35025605
Nakamura Y, Nakajima H, Tani H, Hosokawa T, Ishida S, Kimura F, Kaneko K, Takahashi T, Nakashima I (2017) Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report. BMC Neurol 17:76
pubmed: 28420330
pmcid: 5395865
Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, Weinshenker BG, Shosha E, Lucchinetti CF, Fryer JP, Lopez-Chiriboga AS, Chen JC, Jitprapaikulsan J, McKeon A, Gadoth A, Keegan BM, Tillema JM, Naddaf E, Patterson MC, Messacar K, Tyler KL, Flanagan EP (2019) Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 76:301–309
pubmed: 30575890
Oliveira LM, Apostolos-Pereira SL, Pitombeira MS, Bruel Torretta PH, Callegaro D, Sato DK (2019) Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler 25:1907–1914
pubmed: 30417715
Di Pauli F, Berger T (2018) Myelin oligodendrocyte glycoprotein antibody-associated disorders: toward a new spectrum of inflammatory demyelinating CNS disorders? Front Immunol 9:2753
pubmed: 30555462
pmcid: 6281762
Nanishi E, Hoshina T, Sanefuji M, Kadoya R, Kitazawa K, Arahata Y, Sato T, Hirayama Y, Hirai K, Yanai M, Nikaido K, Maeda A, Torisu H, Okada K, Sakai Y, Ohga S (2019) A nationwide survey of pediatric-onset Japanese encephalitis in Japan. Clin Infect Dis 68:2099–2104
pubmed: 30252025
Chong PF, Kira R, Mori H, Okumura A, Torisu H, Yasumoto S, Shimizu H, Fujimoto T, Hanaoka N, Kusunoki S, Takahashi T, Oishi K, Tanaka-Taya K, Acute Flaccid Myelitis Collaborative Study I (2018) Clinical features of acute flaccid myelitis temporally associated with an enterovirus D68 outbreak: results of a nationwide survey of acute flaccid paralysis in Japan, August-December 2015. Clin Infect Dis 66:653–664
Schneier AJ, Shields BJ, Hostetler SG, Xiang H, Smith GA (2006) Incidence of pediatric traumatic brain injury and associated hospital resource utilization in the United States. Pediatrics 118:483–492
pubmed: 16882799
Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, Ghezzi A, Hintzen R, Kornberg A, Pohl D, Rostasy K, Tenembaum S, Wassmer E, International Pediatric Multiple Sclerosis Study G (2013) International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19:1261–1267
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173
pubmed: 29275977
Torisu H, Kira R, Ishizaki Y, Sanefuji M, Yamaguchi Y, Yasumoto S, Murakami Y, Shimono M, Nagamitsu S, Masuzaki M, Amamoto M, Kondo R, Uozumi T, Aibe M, Gondo K, Hanai T, Hirose S, Matsuishi T, Shirahata A, Mitsudome A, Hara T (2010) Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 32:454–462
pubmed: 19942388
Yamaguchi Y, Torisu H, Kira R, Ishizaki Y, Sakai Y, Sanefuji M, Ichiyama T, Oka A, Kishi T, Kimura S, Kubota M, Takanashi J, Takahashi Y, Tamai H, Natsume J, Hamano S, Hirabayashi S, Maegaki Y, Mizuguchi M, Minagawa K, Yoshikawa H, Kira J, Kusunoki S, Hara T (2016) A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology 87:2006–2015
pubmed: 27742816
pmcid: 5109945
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMOD (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189
Torio M, Iwayama M, Sawano T, Inoue H, Ochiai M, Taira R, Yonemoto K, Ichimiya Y, Sonoda Y, Sasazuki M, Ishizaki Y, Sanefuji M, Yamane K, Yamashita H, Torisu H, Kira R, Hara T, Kanba S, Sakai Y, Ohga S (2021) Neurodevelopmental outcomes of high-risk preterm infants: a prospective study in Japan. Neurol Clin Pract 11:398–405
pubmed: 34840866
pmcid: 8610512
Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakazawa T, Nakashima I (2022) Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD. J Neurol Sci 437:120269
pubmed: 35483239
Boesen MS, Blinkenberg M, Thygesen LC, Ilginiene J, Langkilde AR (2022) Magnetic resonance imaging criteria at onset to differentiate pediatric multiple sclerosis from acute disseminated encephalomyelitis: A nationwide cohort study. Mult Scler Relat Disord 62:103738
pubmed: 35452961
Tetsuhara K, Kaku N, Watanabe Y, Kumamoto M, Ichimiya Y, Mizuguchi S, Higashi K, Matsuoka W, Motomura Y, Sanefuji M, Hiwatashi A, Sakai Y, Ohga S (2021) Predictive values of early head computed tomography for survival outcome after cardiac arrest in childhood: a pilot study. Sci Rep 11:12090
pubmed: 34103642
pmcid: 8187472
Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G, Chandratre S, Hemingway C, Jacob A, Vincent A, Leite MI, Waters P, Palace J (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140:3128–3138
pubmed: 29136091
Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, Vucic S, Gorman MP, Benson LA, Alper G, Riney CJ, Barnett M, Parratt JD, Hardy TA, Leventer RJ, Merheb V, Nosadini M, Fung VS, Brilot F, Dale RC (2016) Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 22:470–482
pubmed: 26163068
Tenembaum S, Yeh EA, Guthy-Jackson Foundation International Clinical C (2020) Pediatric NMOSD: a review and position statement on approach to work-up and diagnosis. Front Pediatr 8:339
de Mol CL, Wong YYM, van Pelt ED, Ketelslegers IA, Bakker DP, Boon M, Braun KPJ et al (2018) Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study. J Neurol 265:1310–1319
pubmed: 29569176
pmcid: 5990581
Beiske AG, Pedersen ED, Czujko B, Myhr KM (2004) Pain and sensory complaints in multiple sclerosis. Eur J Neurol 11:479–482
pubmed: 15257687
Rae-Grant AD, Eckert NJ, Bartz S, Reed JF (1999) Sensory symptoms of multiple sclerosis: a hidden reservoir of morbidity. Mult Scler 5:179–183
pubmed: 10408718
Osterberg A, Boivie J, Thuomas KA (2005) Central pain in multiple sclerosis–prevalence and clinical characteristics. Eur J Pain 9:531–542
pubmed: 16139182
Fabri TL, O’Mahony J, Fadda G, Gur RE, Gur RC, Yeh EA, Banwell BL, Till C (2022) Cognitive function in pediatric-onset relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Mult Scler Relat Disord 59:103689
pubmed: 35183817
Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH (2005) Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 102:13992–13997
pubmed: 16172404
pmcid: 1236555
Zackowski KM, Smith SA, Reich DS, Gordon-Lipkin E, Chodkowski BA, Sambandan DR, Shteyman M, Bastian AJ, van Zijl PC, Calabresi PA (2009) Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain 132:1200–1209
pubmed: 19297508
pmcid: 2677795
Ding YQ, Qi JG (2022) Sensory root demyelination: transforming touch into pain. Glia 70:397–413
pubmed: 34549463
Sechi E, Krecke KN, Pittock SJ, Dubey D, Lopez-Chiriboga AS, Kunchok A, Weinshenker BG, Zalewski NL, Flanagan EP (2021) Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Mult Scler 27:303–308
pubmed: 32103708
Absoud M, Greenberg BM, Lim M, Lotze T, Thomas T, Deiva K (2016) Pediatric transverse myelitis. Neurology 87:S46–52
pubmed: 27572861
Silwal A, Pitt M, Phadke R, Mankad K, Davison JE, Rossor A, DeVile C, Reilly MM, Manzur AY, Muntoni F, Munot P (2018) Clinical spectrum, treatment and outcome of children with suspected diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. Neuromuscul Disord 28:757–765
pubmed: 30072201
pmcid: 6509554
Rinaldi S, Davies A, Fehmi J, Beadnall HN, Wang J, Hardy TA, Barnett MH, Broadley SA, Waters P, Reddel SW, Irani SR, Brilot F, Dale RC, Ramanathan S, Australian, New Zealand MOGSG (2021) Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurol Neuroimmunol Neuroinflamm 8
Tanaka S, Hashimoto B, Izaki S, Oji S, Fukaura H, Nomura K (2020) Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts. Mult Scler Relat Disord 41:102005
pubmed: 32114369
Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Kuker W, Chandratre S, Vincent A, Palace J (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71:276–283
pubmed: 24425068
Doukas SG, Santos AP, Mir W, Daud S, Zivin-Tutela TH (2022) A rare case of myelin oligodendrocyte glycoprotein antibody-associated transverse myelitis in a 40-year-old patient with COVID-19. Cureus 14:e23877
pubmed: 35530898
pmcid: 9074907
Onouchi K, Koga H, Yokoyama K, Yoshiyama T (2014) An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain. J Pain Res 7:439–447
pubmed: 25114584
pmcid: 4122555
Kaneko K, Sato DK, Nakashima I, Ogawa R, Akaishi T, Takai Y, Nishiyama S, Takahashi T, Misu T, Kuroda H, Tanaka S, Nomura K, Hashimoto Y, Callegaro D, Steinman L, Fujihara K, Aoki M (2018) CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry 89:927–936
pubmed: 29875186
Dong Y, D’Mello C, Pinsky W, Lozinski BM, Kaushik DK, Ghorbani S, Moezzi D, Brown D, Melo FC, Zandee S, Vo T, Prat A, Whitehead SN, Yong VW (2021) Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia. Nat Neurosci 24:489–503
pubmed: 33603230
Kihara Y, Matsushita T, Kita Y, Uematsu S, Akira S, Kira J, Ishii S, Shimizu T (2009) Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc Natl Acad Sci U S A 106:21807–21812
pubmed: 19995978
pmcid: 2789753
Masuda T, Sankowski R, Staszewski O, Bottcher C, Amann L, Sagar SC, Nessler S, Kunz P, van Loo G, Coenen VA, Reinacher PC, Michel A, Sure U, Gold R, Grun D, Priller J, Stadelmann C, Prinz M (2019) Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566:388–392
pubmed: 30760929
Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A, Walker AJ, Gergits F, Segel M, Nemesh J, Marsh SE, Saunders A, Macosko E, Ginhoux F, Chen J, Franklin RJM, Piao X, McCarroll SA, Stevens B (2019) Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity 50(253–271):e256
Sugimoto K, Mori M, Liu J, Tanaka S, Kaneko K, Oji S, Takahashi T, Uzawa A, Uchida T, Masuda H, Ohtani R, Nomura K, Hiwasa T, Kuwabara S (2019) The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. J Neuroimmunol 336:577021
pubmed: 31473520